Cantor on Sarepta (SRPT) Post FDA Briefing Docs: 'we think there could be some pressure on the stock today'
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $158.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
